


THE DANGERS OF DELAYED ACCESS

TO CLINICAL TRIAL DATA

**DELAYED CLINICAL
DATA DELIVERY
IS A GROWING
PROBLEM**




62% of respondents do not get all of their data in real-time.

The issue is particularly pressing with biomarker data, **13%** of which may not be available until the trial has ended, eliminating its value in developing and delivering precision medicine.




**WITHOUT TIMELY ACCESS TO DATA,
SERIOUS ISSUES GO UNDETECTED**




TOP ISSUES EXPERIENCED IN ACCESSING REAL-TIME CLINICAL TRIAL DATA



Data entry delays




Cleaning backlog




Complex edit checks




Inconsistent data formats




Meta data for different sources



Latency issues with the system




Missing data




Inaccurate data

HOW LONG DOES IT TAKE TO RECEIVE CLINICAL TRIAL DATA FROM INTERNAL AND EXTERNAL PARTNERS, ONCE IT HAS BEEN REQUESTED?



Legend: 1 day, 1 week, 2 weeks, 3-9 weeks, 10 weeks, End of trial, N/A

**REAL-TIME ACCESS TO CLINICAL
TRIAL DATA CAN REVOLUTIONIZE
YOUR CLINICAL TRIALS**



Visit remarquesystems.com to learn how we can help you optimize your clinical trial data, maximize return and minimize risk.

**READ MORE: IS A LACK OF REAL-TIME
DATA HOLDING TRIALS BACK?**

<https://pharmaphorum.com/r-d/is-a-lack-of-real-time-data-holding-trials-back>

REMARQUE
SYSTEMS™

SOURCE:

• ¹Challenges And Opportunities In Clinical Data Management RESEARCH REPORT 2018 by: Pharma Intelligence

• ²Ibid.

• ³Ibid.

• ⁴Ibid.

© 2020 REMARQUE SYSTEMS. ALL RIGHTS RESERVED.